BioSpace News Archive

XOMA Corporation announced the pricing of its underwritten registered public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share at an initial public offering price of $25.00 per share, raising gross proceeds of $22.0 million before deducting underwriting discounts, the structuring fee and other estimated offering expenses.

FDA expected to make a decision on Emergency Use Authorization in the coming days Positive vote based on totality of scientific evidence presented by the companies, including Phase 3 efficacy and safety data If authorized, BNT162b2 would be the first COVID-19 vaccine available in the U.S.

Applied BioCode announced today that it has received Emergency Use Authorization (EUA) from the US FDA for the use of its BioCode® SARS CoV-2 molecular diagnostic assay with pooled patient samples*. Applied BioCode’s EUA permits the pooled testing of up to five individual specimens from patients suspected of having COVID-19. The BioCode® SARS CoV-2 Assay is run on the automated BioCode® MDx-3000 Molecular System

Ziopharm Continues to Recommend that Shareholders Support Company’s Strong Progress by Returning the GREEN Consent Revocation Card

- We as Canadians pride ourselves on our commitment to each other. By getting vaccinated, we protect one another and our way of life. Vaccines are safe, effective and one of the best ways to prevent serious illness like COVID-19. Vaccines are only approved in Canada after thorough and independent review of the scientific evidence. They a

- Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has accepte

Certara, Inc. (“Certara”), a global leader in biosimulation, today announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at $23.00 per share. Certara is offering 14,630,000 shares of its common stock and certain selling stockholders are offering 14,425,000 shares of common stock in the offering. Shares of Certara’s common stock are expected to begin trading on The Nasdaq Gl

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation Committee of Mirum’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 11,300 shares of common stock to one new employee under Mirum’s 2020 Indu

Colorado BioScience Association celebrated the companies and organizations driving new health innovations to save and change lives around the world during its Annual Awards Celebration. The seventeenth annual event, held virtually on December 9, brought together life sciences leaders and innovators working through the pandemic on breakthrough

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first patient has been successfully enrolled a